Tau Seeding Models
Recapitulate the key structural features and spreading of tau pathology found in the brain of Alzheimer’s disease and other tauopathy patients
Injection of brain extract from Tauopathy patients in the mouse brain locally induces Tau pathology. The induced Tau pathology strongly mimics the lesions found in human AD and other Tauopathy patients and accordingly spreads to other brain regions.
Take advantage of InnoSer’s preclinical research expertise in modelling Tau pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience with modelling Tau pathology in vivo and are happy to help guide your decision on study design fit for your current research goals.
Tau seeding models key characteristics:
- Human brain-derived or recombinant Tau aggregates.
- Injections in transgenic or humanized Tau mice.
- Tau seeding in amyloid models allows simultaneous modelling of both AD pathologies.
- Injection of Tau seeds in transgenic Tau mice with FTD-related mutations leads to rapid and aggressive induction and propagation of Tau pathology.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Key readouts
Test the efficacy of your treatments in the following battery of cognitive behavioural tests:
Test the efficacy of your treatments with the following biological readouts:
- MSD: Plasma, CSF and brain (phosphorylated Tau, cytokines, NF-L)
- (Digital) histopathology
- Immunohistochemistry (e.g., pTau, neuroinflammation.)
Progression of Tau pathology in the weeks after infusion of human Tau seeds into the hippocampus of Tau mice, as detected by AT8 fluorescent staining.
Human Tau seeds isolated from human AD brain tissue induce AT8-positive Tau cells in Tau mice.
The number of Tau inclusions and associated neuroinflammation or neurodegeneration can be quantified after immunohistochemical (IHC) staining of brain slices. The spreading of Tau pathology can be assessed by examining brain regions distant from the injection site. In addition, we measure (phosphorylated) Tau levels in the brain, cerebrospinal fluid, and blood using ultra-sensitive immunoassays (i.e., MSD, Simoa).
Related Alzheimer’s disease model options
Neurology Platform Overview
Transgenic Tau Models
Transgenic Amyloid Models
InnoSer offers preclinical research services with several different transgenic amyloid models, which recapitulate the plaque pathology of AD.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know